Dyne wins new Outperform at BMO

Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated by Analysts at BMO Capital Markets
Stock analysts at BMO Capital Markets started coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a report released on Wednesday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $50.
Dyne Therapeutics initiated with an Outperform at BMO Capital
BMO Capital analyst Kostas Biliouris initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $50 price target The firm
BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating
BMO Capital Markets initiated coverage on Dyne Therapeutics (DYN, Financials) with an Outperform rating and a $50 price target, suggesting a strong upside from the company's current share price of $12.
Dyne Therapeutics’ (DYN) Buy Rating Reiterated at Chardan Capital
Chardan Capital reaffirmed their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN – Free Report) in a report issued on Friday,Benzinga reports. They currently have a $50.00 target price on the stock.
BMO Capital Initiates Coverage of Dyne Therapeutics (DYN) with Outperform Recommendation
Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Dyne Therapeutics (NasdaqGS:DYN) with a Outperform recommendation. As of March 4, 2025, the average one-year price target ...
Dyne wins new Outperform at BMO on prospects for lead drug
Dyne Therapeutics (DYN) stock gains premarket momentum as BMO Capital Markets issus a new Outperform rating on the company. Read more here.
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...
Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker
Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.
Dyne Therapeutics price target lowered to $48 from $53 at Piper Sandler
Piper Sandler lowered the firm’s price target on Dyne Therapeutics (DYN) to $48 from $53 following ATM dilution, while keeping an Overweight ...
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced ...
manilatimes17d
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Full enrollment of Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 Planned for Mid-2025 to Support Submission for U.S. Accelerated Approval - - Full Enrollment of Registrational ...